Julie Grant leads investments in biopharma and digital health companies at Canaan and is laser focused on identifying companies that will tangibly improve patient care. In 2015, Julie led the Series C financing for Protagonist Therapeutics (PTGX), which is developing orally stable peptides to treat autoimmune disorders. The company went public in 2016 and entered into a $990 million partnership with Janssen Pharmaceuticals in 2017.
During her time at Canaan, Julie also led the investment for Cellular Research and supported Dermira, Labrys Biologics, CytomX, Unchained Labs, Chrono Therapeutics, Genome Medical, Glooko and Truveris. Julie serves on the board of the Biden Cancer Initiative. She also co-chairs Planned Parenthood Northern California's IT Advisory Board. In 2017 Julie was named one of Silicon Valley Business Times' 40 Under 40.
A seasoned athlete, Julie biked 4000 miles across the country to raise money for Habitat for Humanity, and was a college sailing national champion.
Prior to joining Canaan, Julie worked at Genentech to bring oncology products to market, holding roles in development, business development and marketing. She holds an M.B.A. from Stanford's Graduate School of Business, a M.Phil. from Cambridge University in BioScience Enterprise and a B.S. in Molecular Biophysics and Biochemistry from Yale University.